Value proposition

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer.

The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients.

Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets.

Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities.

MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.


Therapeutic antibodies, Infectious disease, Human antibodies, Antibody repertoire, antibodyome, High throughput, single B cell, and Antibody discovery